2024
Improving Guideline-Concordant Care for Febrile Infants Through a Quality Improvement Initiative.
McDaniel C, Kerns E, Jennings B, Magee S, Biondi E, Flores R, Aronson P. Improving Guideline-Concordant Care for Febrile Infants Through a Quality Improvement Initiative. 2024, 153 PMID: 38682245, DOI: 10.1542/peds.2023-063339.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesFebrile infantsAmerican Academy of Pediatrics clinical practice guidelineSecondary measuresAAP clinical practice guidelinesPediatrics clinical practice guidelineInvasive bacterial infectionsQI collaborativeIntervention bundleAdherence to specific recommendationsDischarge of infantsGuideline-concordant careInfants aged 8Clinical practice guideline recommendationsPrimary measureQuality improvementOral antibioticsEmergency department dischargePositive urinalysisAssociated with improvementsQualifying infantsQuality improvement initiativesAdministered antibioticsGuideline recommendationsCerebrospinal fluid
2022
Lipid‐lowering treatment among older patients with atherosclerotic cardiovascular disease
Nanna M, Nelson A, Haynes K, Shambhu S, Eapen Z, Cziraky M, Calvert S, Pagidipati N, Granger C. Lipid‐lowering treatment among older patients with atherosclerotic cardiovascular disease. Journal Of The American Geriatrics Society 2022, 71: 1243-1249. PMID: 36538393, PMCID: PMC10089944, DOI: 10.1111/jgs.18172.Peer-Reviewed Original ResearchConceptsHigh-intensity statinsLipid-Lowering TherapyModerate-intensity statinsU.S. older adultsOlder adultsPCSK9 inhibitorsNon-statin lipid-lowering therapyMulticenter retrospective cohort studyRetrospective cohort studyMinority of patientsAtherosclerotic cardiovascular diseaseCoronary artery diseaseEligible older adultsCohort studyOlder patientsOverall cohortArtery diseaseIntensive treatmentCardiovascular diseaseASCVDSecondary measuresStatinsUntreated individualsPatientsTherapyNaltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. American Journal Of Psychiatry 2022, 179: 927-937. PMID: 36285406, PMCID: PMC9722598, DOI: 10.1176/appi.ajp.20220267.Peer-Reviewed Original ResearchConceptsBehavioral weight loss therapyBinge-eating disorderPlacebo groupBupropion groupWeight lossRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialLogistic regressionBinge-eating remissionPlacebo-controlled trialWeight loss therapyDouble-blind placeboSerious public health problemPublic health problemEvidence-based treatmentsRate of participantsBinge-eating frequencyBinge Eating DisorderMedical comorbiditiesRemission rateLoss therapyPercent weight lossMixed modelsFunctional impairmentSecondary measures
2021
An Initiative to Decrease Laboratory Testing in a NICU
Klunk CJ, Barrett RE, Peterec SM, Blythe E, Brockett R, Kenney M, Natusch A, Thursland C, Gallagher PG, Pando R, Bizzarro MJ. An Initiative to Decrease Laboratory Testing in a NICU. 2021, 148: e2020000570. PMID: 34088759, DOI: 10.1542/peds.2020-000570.Peer-Reviewed Original ResearchMeSH KeywordsBilirubinBlood GlucoseBlood VolumeCarbon DioxideConnecticutHemorrhageHospitals, PediatricHumansInfant, NewbornIntensive Care Units, NeonatalLaboratories, HospitalMonitoring, PhysiologicPainPoint-of-Care TestingProcedures and Techniques UtilizationQuality ImprovementUnnecessary ProceduresConceptsExtreme laboratory valuesPatient daysLaboratory valuesOutcome measuresMultifaceted quality improvement projectSerum bilirubin testSecondary outcome measuresPrimary outcome measureHealthcare Improvement's ModelNotable adverse effectsLaboratory testingQuality improvement projectOrder of interventionsBlood lossNeurodevelopmental impairmentBlood glucoseSecondary measuresSustained reductionBilirubin testBlood volumeGuideline developmentLaboratory testsUnnecessary testsNICUAdverse effects
2019
Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial
Shannahoff-Khalsa D, Fernandes RY, de B. Pereira C, March JS, Leckman JF, Golshan S, Vieira MSR, Polanczyk GV, Miguel EC, Shavitt RG. Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial. Frontiers In Psychiatry 2019, 10: 793. PMID: 31780963, PMCID: PMC6859828, DOI: 10.3389/fpsyt.2019.00793.Peer-Reviewed Original ResearchY-BOCS scoresFirst-line therapyObsessive-compulsive disorderClinical trialsSecondary measuresY-BOCSShort Form-36 Health SurveyBaseline Y-BOCS scoresCompulsive ScaleGreater improvementRelative efficacyClinical Global ImpressionEffective treatment scheduleYale-Brown Obsessive Compulsive ScaleHigh psychosocial impairmentBeck Depression InventoryBeck Anxiety InventoryLife-long disorderObsessive Compulsive ScaleYale-Brown ObsessiveYoga meditationLine therapyPrimary outcomeTreat analysisReuptake inhibitorsRandomized, Sham-Controlled Trial of Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Tics in Adolescents With Tourette Syndrome
Sukhodolsky DG, Walsh C, Koller WN, Eilbott J, Rance M, Fulbright RK, Zhao Z, Bloch MH, King R, Leckman JF, Scheinost D, Pittman B, Hampson M. Randomized, Sham-Controlled Trial of Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Tics in Adolescents With Tourette Syndrome. Biological Psychiatry 2019, 87: 1063-1070. PMID: 31668476, PMCID: PMC7015800, DOI: 10.1016/j.biopsych.2019.07.035.Peer-Reviewed Original ResearchConceptsSupplementary motor areaYale Global Tic Severity ScaleFunctional magnetic resonanceTic Severity ScaleReal-time functional magnetic resonanceTourette syndromeSeverity ScaleYale Global Tic Severity Scale-Total Tic ScoreTotal tic scorePrimary outcome measureSham control conditionReduction of ticsMagnetic resonanceSecondary outcomesSessions of neurofeedbackCrossover studyTic symptomsTic scoreOutcome measuresMotor areaSecondary measuresTic severityReal neurofeedbackEnd pointNeurofeedback interventionComparing Outcomes of Women‐Only and Mixed‐Gender Intensive Posttraumatic Stress Disorder Treatment for Female Veterans
Stefanovics EA, Rosenheck RA. Comparing Outcomes of Women‐Only and Mixed‐Gender Intensive Posttraumatic Stress Disorder Treatment for Female Veterans. Journal Of Traumatic Stress 2019, 32: 606-615. PMID: 31361360, DOI: 10.1002/jts.22417.Peer-Reviewed Original ResearchConceptsFemale veteransMixed-gender programsOutcomes of womenNational program evaluation dataPosttraumatic stress disorder (PTSD) treatmentProgram entryLonger lengthTotal PTSD symptomsPTSD total scoreBaseline characteristicsPrimary outcomePTSD symptom levelsComparing outcomesSecondary measuresWomen veteransAssessment subscaleDisorders ProgramPosttraumatic Stress Disorder (CR for PTSD) programDisorder treatmentOutcome assessmentSuperior outcomesProgram evaluation dataPTSD symptomsSymptom levelsTotal score
2017
Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma
Berry JL, Bechtold M, Shah S, Zolfaghari E, Reid M, Jubran R, Kim JW. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma. Ophthalmology 2017, 124: 1817-1825. PMID: 28655537, DOI: 10.1016/j.ophtha.2017.05.034.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChildChild, PreschoolCryotherapyEtoposideFemaleFollow-Up StudiesHumansInfantInfusions, IntravenousIntravitreal InjectionsLaser CoagulationMaleMelphalanNeoplasm SeedingRetinal NeoplasmsRetinoblastomaRetrospective StudiesSalvage TherapyVincristineVitreous BodyConceptsIntra-arterial chemotherapyIntravitreal melphalanIntravenous chemotherapyVitreous seedingSalvage rateRetrospective reviewIVM injectionsOverall globe salvage ratePrimary intra-arterial chemotherapyGlobe salvage rateNonrandomized retrospective reviewOutcome of retinoblastomaRecurrent vitreous seedingPrimary outcome measureActive retinoblastomaVitreous seedsGlobe salvageIntravitreal chemotherapySingle centerIntravitreal injectionMore injectionsGrade 3Outcome measuresSecondary measuresEffective treatment
2016
Evaluation of Motivational Interviewing to Improve Psychotropic Medication Adherence in Adolescents
Hamrin V, Iennaco JD. Evaluation of Motivational Interviewing to Improve Psychotropic Medication Adherence in Adolescents. Journal Of Child And Adolescent Psychopharmacology 2016, 27: 148-159. PMID: 27487472, DOI: 10.1089/cap.2015.0187.Peer-Reviewed Original ResearchConceptsDrug Attitude InventoryPsychotropic medication adherenceMedication adherenceAdherence scoreSelf-reported adherence scoreUniversity mental health centerElectronic adherence dataSelf-rated adherenceMedication adherence ratesBaseline mean scoresMental health centersPoor mental health outcomesMean scoreSignificant differencesMental health outcomesWorld Health OrganizationMedication nonadherenceMood stabilizersAdherence ratesHealth centersNurse practitionersSecondary measuresAdherence dataPostintervention assessmentsMEMS caps
2015
LONG‐TERM OUTCOME IN PEDIATRIC TRICHOTILLOMANIA
Schumer MC, Panza KE, Mulqueen JM, Jakubovski E, Bloch MH. LONG‐TERM OUTCOME IN PEDIATRIC TRICHOTILLOMANIA. Depression And Anxiety 2015, 32: 737-743. PMID: 26139231, PMCID: PMC4591183, DOI: 10.1002/da.22390.Peer-Reviewed Original ResearchConceptsPoor long-term prognosisLong-term prognosisLong-term outcomesN-acetylcysteineDepressive symptomsPediatric trichotillomaniaTrichotillomania symptomsOlder ageAdequate symptom reliefPlacebo-controlled trialAnxiety symptomsPredictors of outcomePrevious cross-sectional studiesRisk of depressionCross-sectional studyPrimary outcomeSymptom reliefAcute phaseClinical assessmentTreatment utilizationBaseline evaluationSecondary measuresBaseline assessmentSymptomsBehavioral treatment
2013
N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 231-240. PMID: 23452680, PMCID: PMC3745012, DOI: 10.1016/j.jaac.2012.12.020.Peer-Reviewed Original ResearchConceptsN-acetylcysteinePharmacological interventionsPediatric trichotillomaniaBenefit of NACBehavioral therapySecondary outcome measuresTreatment of childrenClinician-rated improvementMassachusetts General HospitalTreat populationPlacebo groupPrimary outcomeNAC groupGeneral HospitalOutcome measuresTreatment respondersSecondary measuresPlaceboTreatment assignmentTrichotillomaniaLinear mixed modelsTrialsSignificant differencesChildrenTherapy
2010
Escitalopram versus placebo in the treatment of dysthymic disorder
Hellerstein DJ, Batchelder ST, Hyler S, Arnaout B, Toba C, Benga I, Gangure D. Escitalopram versus placebo in the treatment of dysthymic disorder. International Clinical Psychopharmacology 2010, 25: 143-148. PMID: 21811192, DOI: 10.1097/yic.0b013e328333c35e.Peer-Reviewed Original ResearchConceptsHamilton Depression Rating ScaleDysthymic disorderGlobal assessmentSelective serotonin reuptake inhibitorsClinical Global Impressions-SeveritySuperiority of escitalopramPercentage of respondersPlacebo-treated individualsSerotonin reuptake inhibitorsDepression Rating ScaleStructured Clinical InterviewPercentage of participantsLarger study sampleItem total scoresSocial Adjustment ScaleAcute efficacyEscitalopram doseHDRS-24Active medicationReuptake inhibitorsWeek 12Inclusion criteriaSecondary measuresEscitalopramClinical Interview
2007
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of Torcetrapib on the Progression of Coronary Atherosclerosis. New England Journal Of Medicine 2007, 356: 1304-1316. PMID: 17387129, DOI: 10.1056/nejmoa070635.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticholesteremic AgentsAtorvastatinBlood PressureCardiovascular DiseasesCholesterol Ester Transfer ProteinsCholesterol, HDLCholesterol, LDLCoronary Artery DiseaseDisease ProgressionDouble-Blind MethodDrug Therapy, CombinationFemaleHeptanoic AcidsHumansMaleMiddle AgedProspective StudiesPyrrolesQuinolinesUltrasonography, InterventionalConceptsAtheroma volumeHDL cholesterolLDL cholesterolAtorvastatin monotherapyCoronary atherosclerosisLipoprotein cholesterolBlood pressureIntravascular ultrasonographyHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolEffects of torcetrapibCholesteryl ester transfer protein inhibitorsPercent atheroma volumeSystolic blood pressureHDL cholesterol levelsLack of efficacyCETP inhibitor torcetrapibMechanism of actionCardiovascular riskSmall favorable effectCholesterol levelsDisease progressionDiseased vessel segmentDrug classesSecondary measuresPositive Effects of Methylphenidate on Inattention and Hyperactivity in Pervasive Developmental Disorders: An Analysis of Secondary Measures
Posey D, Aman M, McCracken J, Scahill L, Tierney E, Arnold L, Vitiello B, Chuang S, Davies M, Ramadan Y, Witwer A, Swiezy N, Cronin P, Shah B, Carroll D, Young C, Wheeler C, McDougle C. Positive Effects of Methylphenidate on Inattention and Hyperactivity in Pervasive Developmental Disorders: An Analysis of Secondary Measures. Biological Psychiatry 2007, 61: 538-544. PMID: 17276750, DOI: 10.1016/j.biopsych.2006.09.028.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChildChild Development Disorders, PervasiveChild, PreschoolCross-Over StudiesDiagnostic and Statistical Manual of Mental DisordersDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMethylphenidatePsychiatric Status Rating ScalesSurveys and QuestionnairesConceptsYale-Brown Obsessive Compulsive ScaleOppositional defiant disorderAttention-deficit/hyperactivity disorderPervasive developmental disorderSequence of placeboChildren's Yale-Brown Obsessive Compulsive ScaleSignificant interindividual variabilityDevelopmental disordersObsessive Compulsive ScaleCrossover studyPelham QuestionnaireOutcome measuresRepetitive behaviorsSecondary measuresMethylphenidate dosesSecondary analysisInterindividual variabilityMethylphenidateDSM-IVDifferent dosesSymptom domainsCompulsive ScaleHyperactivity disorderSymptomsDisordersEfficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
Tran-Johnson T, Sack D, Marcus R, Auby P, McQuade R, Oren D. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. The Journal Of Clinical Psychiatry 2007, 68: 111-9. PMID: 17284138, DOI: 10.4088/jcp.v68n0115.Peer-Reviewed Original ResearchConceptsPrimary efficacy measureIntramuscular aripiprazoleIM haloperidolIM aripiprazoleAcute agitationAdverse eventsEfficacy measuresTreatment-emergent adverse eventsCommon adverse eventsPlacebo-controlled trialPlacebo-controlled studyControl of agitationSchizo-affective disorderDSM-IV diagnosisNegative Syndrome ScaleHaloperidol groupIntramuscular haloperidolExtrapyramidal symptomsMore patientsInitial dosingSchizophreniform disorderMean changePlaceboSecondary measuresPEC scores
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply